Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC and CY as aGVHD Prophylaxis in Allo-BMT for Hematological Malignancies
NCT02270307Phase 3Unknown
- Sponsor
- National Medical Research Center for Hematology
- Start
- Jan 2014
- Primary completion
- Jan 2016
- Modality
- Mesenchymal Stem Cells, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Provacel, cyclophosphamide in graft-versus-host disease (GVHD), sponsored by National Medical Research Center for Hematology. Status: unknown.
02
Drugs
Provacelcyclophosphamide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02270307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02270307.